Orchid Pharma Ltd (LUX:ORCHP)

Q4 2026 Orchid Pharma Ltd Earnings Call Transcript

May 26, 2026 / 11:00 AM GMT

Release Date Price: $5.45

Transcript

Key Points

Positve

Orchid Pharma Ltd (BOM:524372) reported stable Q4 FY26 revenue of approximately Rs 238 crores, signaling a return to business as usual.
The company has seen early signs of recovery and stabilization in gross margins during Q4, indicating a more stable business environment.
Orchid Pharma Ltd is entering a new phase of platform creation, focusing on building a differentiated anti-infective platform.
The merger with Dhanuka Laboratories is expected to contribute to a 1% to 2% EBITDA margin expansion due to synergies.
The company is strategically investing in fill, finish, and formulation capabilities to address regulated sterile formulation opportunities in the U.S. market.

Negative

The global antibiotic industry faced significant pricing and volume pressure, impacting Orchid Pharma Ltd's top-line and profitability.
Standalone revenue for FY26 was Rs 811 crores, down from Rs 922 crores in FY25, reflecting challenging industry conditions.
The company experienced price erosion and downward valuation of inventory, leading to lesser gross margins in the past quarters.
The merger with Dhanuka Laboratories is still awaiting a formal written order, causing delays in realizing potential synergies.
Despite efforts, Orchid Pharma Ltd has not been able to meaningfully participate in the U.S. market due to structural challenges.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ORCD.NS - Orchid Pharma Ltd
Q4 2026 Orchid Pharma Ltd Earnings Call
May 26, 2026 / 11:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to the Orchid Pharma Limited Q4 FY26 earnings con call hosted by Systematics Shares and Stock Limited.

As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes.

Should you need assistance during the conference call, please signal an operator by pressing star, then zero on your touch tone phone. Please note that this conference is being recorded.

I now hand to conference over to Mr. Vishal Manchanda from Systematics.

Thank you very much you sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.